The positive impact that generic and biosimilar medicines have on patients and health systems

December 2020
Market penetration of generic medicines

1. Canada
   - Generic medicines’ market share in volume: 74.4%
   - Generic medicines’ market share in value: 26.6%

2. USA
   - Generic medicines’ market share in volume: 67%
   - Generic medicines’ market share in value: 29%

3. Europe
   - Generic medicines’ market share in volume: 92%
   - Generic medicines’ market share in value: 20%

4. Jordan
   - Generic medicines’ market share in volume: 85%
   - Generic medicines’ market share in value: 69%

5. South Africa
   - Generic medicines’ market share in volume: 97%
   - Generic medicines’ market share in value: 55.1%

6. India
   - Generic medicines’ market share in volume: 71.7%
   - Generic medicines’ market share in value: 55.1%

7. Japan
   - Generic medicines’ market share in volume: 77%
   - Generic medicines’ market share in value: 25.4%

8. Taiwan
   - Generic medicines’ market share in volume: 60/70%

9. Malaysia
   - Generic medicines’ market share in volume: 84%
   - Generic medicines’ market share in value: 28.7%

10. Australia (2019)
    - Generic medicines’ market share in volume: 73%

Source: IGBA membership

14 December 2020
Building on the experience and success of over 300 biosimilar medicines approvals covering over 10 therapeutic areas

A. Canada
B. USA
C. Brazil
D. Argentina
E. Europe
F. Jordan
G. South Africa
H. Japan
I. South Korea
J. Malaysia
K. Taiwan
L. Australia

Number of biosimilar approvals

Source of data: internal IGBA membership

12 November 2020